clinical trial · NCT07363265
Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease
Longbio Pharma·phase2·not yet recruiting·n = 46
Complement-mediated Renal DiseasesLP-005 Injection
brief summary
This is a multicenter, open-label, proof-of-concept, phase Ⅱ adaptive basket clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic profile of LP-005 Injection as add-on therapy to standard treatment in patients with complement-mediated renal diseases.
started
Feb 2, 2026
primary completion
Aug 2, 2028
completion
May 2, 2029
last updated
Jan 23, 2026
official title
A Multicenter, Open-label Phase Ⅱ Study to Evaluate the Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol